STOCK TITAN

Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Azenta has inaugurated a new Genomics Laboratory in Oxford, UK, enhancing its global GENEWIZ Multiomics & Synthesis Solutions. This facility provides UK researchers with advanced NGS platforms and local scientific expertise. The lab aims to expedite high-quality data delivery, fostering progress in critical research areas like diabetes, infectious diseases, and Alzheimer's. The lab features state-of-the-art technology from Illumina, PacBio, Oxford Nanopore, and more. It offers a comprehensive suite of services including library preparation, sequencing, and bioinformatics, supported by Ph.D.-level managers. The opening event on April 25, 2024, included a ribbon-cutting ceremony and lab tour.

Positive
  • New Genomics Lab in Oxford enhances Azenta's global presence.
  • Facilitates faster, high-quality data delivery for UK researchers.
  • Equipped with advanced NGS platforms like Illumina NovaSeq X Plus and PacBio Revio.
  • Local team of top-tier scientists in Oxford.
  • Comprehensive suite of services including library preparation, sequencing, and bioinformatics.
  • Positive collaboration with the local scientific community.
  • Same-day dry ice sample collection in Oxford and Cambridge enhances customer convenience.
Negative
  • No immediate financial data or revenue projections provided, making it difficult to assess direct financial impact.
  • Operational costs of maintaining a high-tech facility in the UK might be significant.

Insights

The opening of Azenta's new Genomics Laboratory in Oxford is a strategic move that could strengthen its position in the competitive genomics market. The facility aims to provide advanced next-generation sequencing (NGS) technology, important for accelerating research in fields like diabetes, infectious diseases and Alzheimer's. For investors, it's important to note that the proximity to Oxford's scientific community and the presence of top-tier talent can enhance the company's reputation and collaboration opportunities. This, in turn, can lead to increased demand for their GENEWIZ Multiomics & Synthesis Solutions.

In the short term, the investment might not significantly impact Azenta’s financials. However, long-term implications include potential revenue growth from expanded service offerings and an enhanced client base within the UK. The competitive advantage derived from state-of-the-art technology and local expertise could position Azenta favorably against its competitors.

Opening a new laboratory is a capital-intensive endeavor. For Azenta, this move signals confidence in the high-growth potential of the genomics market. Investors should focus on the potential return on investment (ROI) from this lab, which hinges on its ability to attract significant business from leading research institutions like the University of Oxford. The unique offerings such as free-of-charge, same-day dry ice sample collection and advanced NGS platforms can be seen as valuable differentiators.

Financially, the success of this lab could lead to higher revenues and margins, assuming operational efficiencies and strong demand. However, investors should monitor initial operating costs and any potential delays in achieving profitability. It's also important to watch for how this expansion aligns with overall corporate strategy and any potential effects on Azenta’s stock performance.

The establishment of a new Genomics Laboratory in Oxford by Azenta is particularly noteworthy for stakeholders in medical research. With advanced platforms like Illumina NovaSeq™ X Plus and Oxford Nanopore Technologies GridION, this facility is well-equipped to support cutting-edge research. The inclusion of local experts with strong ties to Oxford’s scientific community could foster significant advancements in medical research, potentially leading to breakthroughs in understanding and treating complex diseases.

For researchers, the availability of comprehensive NGS services and bioinformatics analysis locally reduces turnaround times and logistical hurdles, enhancing overall research productivity. For investors, this could translate into robust collaborations and partnerships, driving the lab’s utilization rates and, subsequently, Azenta’s revenue growth. Long-term, successful research outcomes facilitated by this lab could bolster Azenta's reputation and market share in the genomics sector.

BURLINGTON, Mass., May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.  The new laboratory brings Azenta closer to UK-based researchers, providing advanced next-generation sequencing (NGS) platforms and a local team of top-tier scientists from Oxford.

"We're thrilled to open our Oxford laboratory, which allows us to bring state-of-the-art NGS technology to UK researchers," said Dr Ginger Zhou, President of Azenta's Multiomics business unit.  "This new facility not only strengthens our global footprint but also offers researchers access to local experts and cutting-edge resources. The Oxford team comprises some of the best minds in the field, all with deep roots in the local scientific community."

The opening event, held on April 25, 2024, featured a ribbon-cutting ceremony, a lab tour, and a celebratory reception with key stakeholders, including members of the local scientific community, distinguished guests, and Azenta executives.

Dr David Buck, Director of Lab Services Oxford added, "This new lab represents our commitment to supporting UK researchers by delivering high-quality data faster, advancing research and development in critical fields such as diabetes, infectious diseases, Alzheimer's and more. We're excited about the energy, engagement, and collaboration with the scientific community, and we look forward to contributing to their success."

"Having an amazing genomics facility like the one Azenta has opened at our doorstep, allows us to work faster, achieving more in less time, with higher accuracy and for an effective cost.  This helps us enhance discovery in medical research to patient benefit." Said Dr. John Todd, Professor of Precision Medicine at the University of Oxford, who attended the opening event.

The Oxford Genomics Laboratory was created with customer convenience in mind.  It offers a network of GENEWIZ collection points plus free-of-charge, same day dry ice sample collection in Oxford, and Cambridge, streamlining the sample submission process for researchers. The lab provides a comprehensive suite of NGS services; library preparation, sequencing, bioinformatics analysis with UK based data storage, plus soon to be, a range of DNA/RNA extraction capabilities, all backed by experienced Ph.D.-level study managers who guide projects from conception to delivery.

GENEWIZ from Azenta is equipped with the latest, cutting-edge NGS platforms globally to enable service users to stay at the forefront of scientific innovation.  Some of these platforms include:  Illumina NovaSeq™ X Plus, PacBio Revio, Oxford Nanopore Technologies GridION, PromethION 2 Solo, 10x Genomics Chromium X, Nanostring GeoMx® & nCounter®, and Olink® Protein Biomarker Detection.

About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Sherry Dinsmore
sherry.dinsmore@azenta.com

Azenta's use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-opens-the-doors-to-its-new-genomics-laboratory-in-oxford-uk-302143963.html

SOURCE Azenta

FAQ

When did Azenta open its new Genomics Laboratory in Oxford, UK?

Azenta opened its new Genomics Laboratory in Oxford on April 25, 2024.

What services does the new Azenta Genomics Lab in Oxford offer?

The lab offers a comprehensive suite of NGS services including library preparation, sequencing, bioinformatics analysis, and DNA/RNA extraction capabilities.

What advanced platforms are available at Azenta's Oxford Genomics Laboratory?

The lab is equipped with advanced NGS platforms such as Illumina NovaSeq X Plus, PacBio Revio, Oxford Nanopore Technologies GridION, and more.

How does the new Azenta Genomics Lab support UK researchers?

The lab provides high-quality, faster data delivery and local scientific expertise, facilitating advancements in critical research areas such as diabetes, infectious diseases, and Alzheimer's.

What customer convenience features does the new Azenta Oxford Lab offer?

The lab offers GENEWIZ collection points, free-of-charge same-day dry ice sample collection in Oxford and Cambridge, and local UK-based data storage.

Azenta, Inc.

NASDAQ:AZTA

AZTA Rankings

AZTA Latest News

AZTA Stock Data

2.29B
44.31M
2.74%
110.56%
8.83%
Medical Instruments & Supplies
Special Industry Machinery, Nec
Link
United States of America
BURLINGTON